Lumos Pharma — NewLink Genetics — Q2 2017 Earnings Presentation
10 slides from Lumos Pharma's earnings presentation, Jul 28, 2017
Slide 1: Second Quarter 2017 Results
NewLink Genetics Corporation Nasdaq: NLNK July 28, 2017 Second Quarter 2017 Results
Slide 2: Agenda
Agenda 2 Introduction Jack Henneman, Executive Vice President & CFO IDO Pathway Program Developments Charles J. Link, Jr., M.D., Chairman, CEO & CSO Clinical Updates / Guidance on Timing of Data Eugene P. Kennedy, M.D., Vice President Clinical & Medical Affairs Second Quarter 2017 Financial Re
Slide 3: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements of NewLink Genetics that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation are forward-looking statements, w
Slide 4: Highlights
Highlights Clinical data continue to support indoximod as a potent IDO pathway inhibitor with the potential to improve outcomes for patients with cancer when used in combination with other cancer therapies Progress toward initiation of a pivotal trial with indoximod for patients with advanced me
Slide 5: Allowed US Patent for Indoximod Formulation (Salt): Potential Market Exclusivity in Advanced Melanoma
Allowed US Patent for Indoximod Formulation (Salt) 5 Potential Market Exclusivity In Advanced Melanoma 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2034 2035 2036 Initiate Pivotal Melanoma Potential US Launch Original US Patent** Expiration Potential EU Launch
Slide 6: Indoximod plus Provenge (sipuleucel-T) Vaccine
Indoximod plus Provenge (sipuleucel-T) Vaccine 46 Patients: Indoximod (22) vs Placebo (24) PA2024 ELISPOT response data showed no statistically significant difference* Statistically significant improvement in radiographic progression free survival (rPFS) – Median rPFS of 10.3 months for indoxi
Slide 7: Indoximod plus Standard of Care Chemotherapy in AML
Indoximod plus Standard of Care Chemotherapy 7 Phase 1/2 Evaluating the Feasibility of Combination with 7+3 Regimen Strong preclinical data and significant unmet need Acute Myeloid Leukemia (AML) Patients with newly diagnosed AML Surrogate efficacy endpoint being explored as potential fast to ma
Slide 8: Clinical Introduction: Indoximod (Salt) Formulation
Clinical Introduction: Indoximod (Salt) Formulation 2H 2017: Phase 1b for patients with AML 2H 2017: Healthy volunteers Q4 2017: Dose escalation phase of pivotal trial 8
Slide 9: Second Quarter 2017 Financial Results
Second Quarter 2017 Financial Results Cash and Equivalents $107.8 million Debt ~$0.4 million YE 2017 Cash (Projected) ~$75 million Forecast Quarterly Negative Cash-Flow1 ~$14 million Shares Outstanding 29.2 million Market Capitalization ~$210 million Headcount2 72 9 1 Excludes the proceeds from any
Slide 10: Q & A
10 Q & A